Acura Pharmaceuticals ( (ACUR) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Acura Pharmaceuticals, Inc. has filed a Form 12b-25 to notify investors of a delay in filing its Form 10-K (Yearly Report) for the year ended December 31, 2025. The company has also left outstanding its Form 10-K (Yearly Report) filings for 2022, 2023, and 2024, as well as all Form 10-Q (Quarter Report) filings for 2022 through 2025.
The primary reason cited is severe liquidity pressure that affects Acura’s ability to meet day-to-day operating obligations. Management notes that operations are currently dependent on loans from Abuse Deterrent Pharma, LLC, and there is no assurance that these loans will continue or be sufficient to support the business over the longer term.
As a result of funding constraints, Acura has halted its public accounting firm’s review of its 2022 and 2023 quarterly results and the audits of its 2022 and 2023 annual results. The company has also not engaged an independent registered public accounting firm to review or audit its 2024 and 2025 quarterly and annual financial statements.
The company indicates that, under the relief sought, the delayed Form 10-K (Yearly Report) could be filed within 15 days of the original due date. However, Acura explicitly warns that it cannot provide any assurance that it will succeed in filing the outstanding Annual Reports and Quarterly Reports or in securing the necessary funding to do so.
Acura states that it does not currently anticipate a significant change in results of operations compared with the prior year for the period covered by the delayed report. Nonetheless, the absence of completed audits and reviews means all forward-looking statements about funding, filings, and operations remain highly uncertain and subject to material change.
The company emphasizes that it assumes no obligation to update the status of its annual audits or quarterly reviews until the pending Form 10-K (Yearly Report) and Form 10-Q (Quarter Report) filings are made with the SEC. The notification is signed on behalf of Acura Pharmaceuticals, Inc. by Senior Vice President and Chief Financial Officer Robert A. Seiser on March 27, 2026, underscoring ongoing but challenged efforts to maintain regulatory compliance.
More about Acura Pharmaceuticals
Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products designed to address medication abuse and misuse. The business model relies on partnerships and external financing to fund operations and advance its product and technology portfolio.
Average Trading Volume: 120
Technical Sentiment Signal: Sell
Current Market Cap: $660K
Learn more about ACUR stock on TipRanks’ Stock Analysis page.